-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Nurix Therapeutics, Raises Price Target to $31

Benzinga·12/10/2025 12:42:40
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $28 to $31.